Net Present Value Model: Venclexta
Powered by
Unlock hidden opportunities in the NPV industry
Overview
Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis.
Drug Operating Profit Model
Venclexta Drug Details
Venetoclax (ABT-199, GDC-0199/RG7601, Venclexta, Venclyxto) acts as an antineoplastic agent. It is formulated as film coated tablets and coated tablets for oral route of administration. Venclexta is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy. Venclyxto monotherapy is indicated for the treatment of CLL in the absence of 17p deletion or TP53mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor, and Venclyxto in combination with rituximab is indicated for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who have received at least one prior therapy. It is used as monotherapy in adults for the treatment of chronic lymphocytic leukemia (CLL), a 1 7p – deletion or TP53 having mutation and under a treatment with an inhibitor of the B – showed a treatment failure cell receptor signaling pathway, and also indicated in combination with azacitidine, ordecitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy and indicated for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Venclyxto (venetoclax) in combination with Gazyvaro (obinutuzumab) is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). Venclexta is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Venclexta is indicated for the treatment of acute myeloid leukemia (AML). It is under development for the treatment of newly diagnosed Ph-like B cell acute lymphoblastic leukemia, relapsed or refractory light chain amyloidosis, relapsed and refractory mantle cell lymphoma, small cell lung cancer, acute myeloid leukemia, follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), newly diagnosed marginal zone lymphoma, acute myeloid leukemia in first remission after conventional chemotherapy, nom-small cell lung cancer as first line therapy, primary mediastinal B-cell lymphoma, T-cell rich B-cell lymphoma and extranodal MALT lymphoma, multiple myeloma, diffuse large B-cell lymphoma, frontline, relapsed or refractory myelodysplastic syndrome, multiple myeloma, DLBCL, metastatic breast cancer, t-cell acute lymphocytic leukemia and relapsed and refractory chronic lymphocytic leukemia (CLL), solid tumors, rhabdomyosarcoma, Ewing sarcoma, Wilms’ tumor (nephroblastoma). It was also under development for follicular lymphoma as first line therapy. It is a new molecular entity (NME). It was under development for non-small cell lung cancer and angioimmunoblastic T-cell lymphoma (AITL). It was also under development for the treatment of human epidermal growth factor receptor 2 negative breast cancer (her2- breast cancer).
Report Coverage
GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
Quick View – NPV Data | |||
Drug Name |
|
||
Administration Pathway |
|
||
Therapeutic Areas | |||
Key Manufacturers |
|
||
Drug Development Status |
|
Reasons to Buy
- Better understand the quantitative value of a specific drug
- Create or support internal NPV models to improve accuracy
- Understand the profit a drug is expected to make, taking into account revenue and cost forecasts leveraging public and proprietary data sets.
Frequently asked questions
- All drug sales and forecasts within NPV Model are calculated in our proprietary company based models . In these models, Analyst Consensus forecasts are built by using company-specific broker reports to create the sales forecasts for each Drug and Segment.
- Sales and forecasts are not indication-specific where drugs are approved , or in development, for multiple indications. Please refer to GlobalData’s Disease Analysis reports for indication-specific sales forecasts.
- Risk-adjusted NPVs use GlobalData’s LoA and PTSR for the indication in the highest development stage. Please refer to the Likelihood of Approval methodology for more details on this content.
GlobalData’s NPV Model is a premium model providing a fully-interactive forecasting and valuation tool, driven by Analyst Consensus estimates, enabling users to analyze and customize valuations for pharmaceutical assets including drugs or segments. The tool provides 17-year drug forecasts from companies with sales forecast data in the pharmaceutical industry, including established global firms and emerging biotechs, which allows access to critical information to facilitate strategic decision making around pharmaceutical assets
The NPV Model includes a forecasted Revenue Model, followed by a proprietary Patent Expiry Model, Operating Profit Model, Net Profit (apply Tax rate) and Discounted Cash Flow (apply Discount rates), to derive Net Present Value (NPV) for a chosen pharmaceutical asset
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.